Zentalis Pharmaceuticals, Inc. (ZNTL:NASDAQ) closed at $2.41 on October 22, 2026, up 2.12% on the day. The stock trades 65.3% below its 52-week high of $6.95 and 98.8% above its 52-week low of $1.21. Over the past year, it gained 47.0%. Zentalis Pharmaceuticals, Inc. is part of the Health Care sector.
In 252 trading sessions since October 22, 2025, ZNTL closed higher on 116 days (46%). Its best day was April 9, 2026 (+60.14%) and its worst was March 27, 2026 (-21.35%). The stock moved 10% or more in a single session 26 times.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
Find more stocks like ZNTL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.